Axogen Inc. (AXGN) 3.37 $AXGN
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 4.89 (-0.03), GPN: 79.23 (-2.46), AXGN: 3.37 (+0.06), ARQL: 1.25 (unch), ELNK: 4.40 (+0.01)
Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:05AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.37 (+0.06)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.37 (+0.06)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" on December 2nd, 2014
Marketwired - Tue Dec 02, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
AXGN: 3.37 (+0.06)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 31.16 (-0.74), AXGN: 3.37 (+0.06), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen
PR Newswire - Fri Nov 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for royalties on certain AxoGen revenues. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:19PM CST
AXGN: 3.37 (+0.06)
AxoGen beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:41PM CST
AXGN: 3.37 (+0.06)
AxoGen, Inc. Signs Agreement with Oberland Capital
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, has entered into a $28.55 million financing agreement with Three Peaks Capital S.a.r.l., an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (collectively "Oberland"
. The financing from Oberland, along with $1.75 million in capital from the Company, enables AxoGen to retire the Company's royalty agreement with PDL BioPharma, Inc. and substantially reduces AxoGen's future annual debt payments.
AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen, Inc. Reports 58% Third Quarter Revenue Growth
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, grew revenue during the third quarter to $4.67 million, up 58% as compared to the year ago third quarter revenue of $2.96 million. The growth was driven by the successful execution of management's growth strategies, which are focused on increasing sales to existing customers and the addition of targeted new customers.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014
GlobeNewswire - Thu Nov 06, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014 after the market closes.
AXGN: 3.37 (+0.06)
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:39AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as its shares rose over 15% on the day.
MNK: 94.72 (-0.36), ACT: 259.00 (-4.00), AXGN: 3.37 (+0.06), MYL: 53.32 (-1.39)
AxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced the presentation of clinical data for Avance(R) Nerve Graft during the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting which took place last week in Boston.
AXGN: 3.37 (+0.06)
Surgeon Attendance at AxoGen's Education Events Exceeds Expectations
GlobeNewswire - Thu Sep 25, 6:02AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported attendance at two recent surgeon education events exceeded management's expectations and registration at two upcoming professional education seminars is near capacity. The event at the American Society for Surgery of the Hand (ASSH) in Boston, held this past week, drew surgeons interested in nerve repair in the upper extremity from the US and multiple other countries. Surgeons focused on repair of the trigeminal nerve in the lower jaw attended an event at the American Association of Oral and Maxillofacial Surgeons (AAOMS) annual meeting in Hawaii.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 16, 6:13AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum at the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting, taking place September 18-20 at the John B. Hynes Convention Center in Boston, MA.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial Surgeons Annual Meeting 2014
GlobeNewswire - Tue Sep 09, 6:04AM CDT
via PRWEB - A xoGen, Inc. (Nasdaq:AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor a panel discussion at the 96th Annual Meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS), taking place this week in Honolulu, HI. The Company will also demonstrate its full portfolio of nerve repair products during the clinical conference at Booth 644.
AXGN: 3.37 (+0.06)
AxoGen, Inc. Announces Changes to Board of Directors
GlobeNewswire - Mon Aug 25, 3:08PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen's Board of Directors.
AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
GlobeNewswire - Tue Aug 05, 6:08AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55am (ET) at Le Parker Meridien Hotel in New York City.
AXGN: 3.37 (+0.06)
AxoGen, Inc. Reports 47% Second Quarter Revenue Growth
GlobeNewswire - Mon Aug 04, 3:07PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced record quarterly revenue of $4.21 million for the second quarter ended June 30, 2014, representing growth of 47% as compared to $2.86 million for the second quarter of 2013. The increase in revenue was driven by increased unit sales to existing customers and the addition of new customers.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
GlobeNewswire - Wed Jul 16, 3:52AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
AXGN: 3.37 (+0.06)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
DXLG: 4.89 (-0.03), GPN: 79.23 (-2.46), AXGN: 3.37 (+0.06), ARQL: 1.25 (unch), ELNK: 4.40 (+0.01)
Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:05AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.37 (+0.06)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.37 (+0.06)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" on December 2nd, 2014
Marketwired - Tue Dec 02, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel -- iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
AXGN: 3.37 (+0.06)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 31.16 (-0.74), AXGN: 3.37 (+0.06), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen
PR Newswire - Fri Nov 14, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for royalties on certain AxoGen revenues. AxoGen is a regenerative medicine company dedicated to advancing the science and commercialization of surgical solutions for peripheral nerve repair.
AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:19PM CST
AXGN: 3.37 (+0.06)
AxoGen beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:41PM CST
AXGN: 3.37 (+0.06)
AxoGen, Inc. Signs Agreement with Oberland Capital
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, has entered into a $28.55 million financing agreement with Three Peaks Capital S.a.r.l., an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (collectively "Oberland"
. The financing from Oberland, along with $1.75 million in capital from the Company, enables AxoGen to retire the Company's royalty agreement with PDL BioPharma, Inc. and substantially reduces AxoGen's future annual debt payments. AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen, Inc. Reports 58% Third Quarter Revenue Growth
GlobeNewswire - Thu Nov 13, 3:09PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, grew revenue during the third quarter to $4.67 million, up 58% as compared to the year ago third quarter revenue of $2.96 million. The growth was driven by the successful execution of management's growth strategies, which are focused on increasing sales to existing customers and the addition of targeted new customers.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014
GlobeNewswire - Thu Nov 06, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014 after the market closes.
AXGN: 3.37 (+0.06)
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:39AM CDT
AxoGen, Inc. (AXGN) was a big mover last session, as its shares rose over 15% on the day.
MNK: 94.72 (-0.36), ACT: 259.00 (-4.00), AXGN: 3.37 (+0.06), MYL: 53.32 (-1.39)
AxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced the presentation of clinical data for Avance(R) Nerve Graft during the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting which took place last week in Boston.
AXGN: 3.37 (+0.06)
Surgeon Attendance at AxoGen's Education Events Exceeds Expectations
GlobeNewswire - Thu Sep 25, 6:02AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported attendance at two recent surgeon education events exceeded management's expectations and registration at two upcoming professional education seminars is near capacity. The event at the American Society for Surgery of the Hand (ASSH) in Boston, held this past week, drew surgeons interested in nerve repair in the upper extremity from the US and multiple other countries. Surgeons focused on repair of the trigeminal nerve in the lower jaw attended an event at the American Association of Oral and Maxillofacial Surgeons (AAOMS) annual meeting in Hawaii.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting
GlobeNewswire - Tue Sep 16, 6:13AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum at the American Society for Surgery of the Hand (ASSH) 2014 Annual Meeting, taking place September 18-20 at the John B. Hynes Convention Center in Boston, MA.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial Surgeons Annual Meeting 2014
GlobeNewswire - Tue Sep 09, 6:04AM CDT
via PRWEB - A xoGen, Inc. (Nasdaq:AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor a panel discussion at the 96th Annual Meeting of the American Association of Oral and Maxillofacial Surgeons (AAOMS), taking place this week in Honolulu, HI. The Company will also demonstrate its full portfolio of nerve repair products during the clinical conference at Booth 644.
AXGN: 3.37 (+0.06)
AxoGen, Inc. Announces Changes to Board of Directors
GlobeNewswire - Mon Aug 25, 3:08PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen's Board of Directors.
AXGN: 3.37 (+0.06), PDLI: 7.41 (-0.08)
AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
GlobeNewswire - Tue Aug 05, 6:08AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55am (ET) at Le Parker Meridien Hotel in New York City.
AXGN: 3.37 (+0.06)
AxoGen, Inc. Reports 47% Second Quarter Revenue Growth
GlobeNewswire - Mon Aug 04, 3:07PM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced record quarterly revenue of $4.21 million for the second quarter ended June 30, 2014, representing growth of 47% as compared to $2.86 million for the second quarter of 2013. The increase in revenue was driven by increased unit sales to existing customers and the addition of new customers.
AXGN: 3.37 (+0.06)
AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
GlobeNewswire - Wed Jul 16, 3:52AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
AXGN: 3.37 (+0.06)
